Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors by Shannon S. Zhang, MD, Sai-Hong Ignatius Ou, MD, PhD

Get full text

Tumor Mutation Burden Survey of AACR GENIE Database Revealed NTRK (NTRK+) and RET (RET+) Fusions Positive Colorectal Carcinoma (CRC) as Distinct Subsets by Zhaohui Liao Arter, Alexandria T. M. Lee, Misako Nagasaka, Sai‐Hong Ignatius Ou

Get full text

Treatment of Choroidal Metastasis from Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer with First-line Osimertinib Therapy by Anderson N. Vu, Urmi V. Mehta, Paul Israelsen, Sai-Hong Ignatius Ou, Andrew W. Browne

Get full text

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability by Hui Wang, Zhi‐Wei Li, Qiuxiang Ou, Xue Wu, Misako Nagasaka, Yang Shao, Sai‐Hong Ignatius Ou, Yu Yang

Get full text

In Response to Dr. Steven Sorscher by Shannon S. Zhang, MD, Alexa B. Schrock, PhD, Misako Nagasaka, MD PhD, Sai-Hong Ignatius Ou, MD, PhD

Get full text

Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab by Michael Lopez, Garo Hagopian, Linda Doan, Benjamin J. Lee, Nathan W. Rojek, Janellen Smith, Sai-Hong Ignatius Ou, Yesim Yilmaz Demirdag, Misako Nagasaka

Get full text

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advance... by Tianhong Li, Patricia LoRusso, Michael L. Maitland, Sai-Hong Ignatius Ou, Erkut Bahceci, Howard A. Ball, Jung Wook Park, Geoffrey Yuen, Anthony Tolcher

Get full text

Clinical and molecular characteristics of Chinese non‐small cell lung cancer patients with ERBB2 transmembrane domain mutations by Yun Fan, Jinrong Qiu, Ruoying Yu, Ran Cao, Xiaoxi Chen, Qiuxiang Ou, Xue Wu, Yang W. Shao, Misako Nagasaka, Jiexia Zhang, Sai‐Hong Ignatius Ou

Get full text

Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer by Kaleem Anwar, PharmD, Lee Nguyen, PharmD, Misako Nagasaka, MD, PhD, Sai-Hong Ignatius Ou, MD, PhD, Alexandre Chan, PharmD, MPH

Get full text

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study by Yongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu, Wenxian Wang, Sai-Hong Ignatius Ou, Jiexia Zhang, Zhengbo Song, Nong Yang

Get full text

A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature by Shannon S. Zhang, MD, Jessica K. Lee, MSc, Hanna Tukachinsky, PhD, Alexa B. Schrock, PhD, Misako Nagasaka, MD, PhD, Sai-Hong Ignatius Ou, MD, PhD

Get full text

Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing by Misako Nagasaka, Shannon S. Zhang, Yasmine Baca, Joanne Xiu, Jorge Nieva, Ari Vanderwalde, Jeffrey J. Swensen, David Spetzler, Wolfgang Michael Korn, Luis E. Raez, Stephen V. Liu, Sai-Hong Ignatius Ou

Get full text

Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real‐world genomic datasets by Santiago Viteri, Anna Minchom, Lyudmila Bazhenova, Sai‐Hong Ignatius Ou, Joshua M. Bauml, Scott A. Shell, Michael Schaffer, Junchen Gu, Jennifer B. Rose, Joshua C. Curtin, Parthiv Mahadevia, Nicolas Girard

Get full text

Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements by Yongchang Zhang, Zhe Huang, Liang Zeng, Xiangyu Zhang, Yizhi Li, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu, Wenxian Wang, Zhengbo Song, Sai-Hong Ignatius Ou, Nong Yang

Get full text

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset by Misako Nagasaka, Danielle Brazel, Yasmine Baca, Joanne Xiu, Mohammed Najeeb Al-Hallak, Chul Kim, Jorge Nieva, Jeffrey J. Swensen, David Spetzler, Wolfgang Michael Korn, Mark A. Socinski, Luis E. Raez, Balazs Halmos, Sai-Hong Ignatius Ou

Get full text

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations by Sai-Hong Ignatius Ou, MD, Huamao M. Lin, PhD, MBA, Jin-Liern Hong, PhD, Yu Yin, MS, MPH, Shu Jin, MS, Jianchang Lin, PhD, Minal Mehta, MBBS, Danny Nguyen, MD, Joel W. Neal, MD, PhD

Get full text

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors by Jessica K. Lee, Smruthy Sivakumar, Alexa B. Schrock, Russell Madison, David Fabrizio, Ole Gjoerup, Jeffrey S. Ross, Garrett M. Frampton, Pavel Napalkov, Meagan Montesion, Jennifer L. Schutzman, Xin Ye, Priti S. Hegde, Misako Nagasaka, Geoffrey R. Oxnard, Ethan S. Sokol, Sai-Hong Ignatius Ou, Zhen Shi

Get full text

ERBB family fusions are recurrent and actionable oncogenic targets across cancer types by Laura Schubert, Andrew Elliott, Anh T. Le, Adriana Estrada-Bernal, Robert C. Doebele, Emil Lou, Hossein Borghaei, Michael J. Demeure, Razelle Kurzrock, Joshua E. Reuss, Sai-Hong Ignatius Ou, David R. Braxton, Christian A. Thomas, Sourat Darabi, Wolfgang Michael Korn, Wafik S. El-Deiry, Stephen V. Liu

Get full text

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report by Rohit Thummalapalli, MD, Noura J. Choudhury, MD, Fiona Ehrich, MS, Tyler Beardslee, PharmD, Danielle Brazel, MD, Shannon S. Zhang, MD, Shelby Merchant, PharmD, Monica F. Chen, MD, Glenn Heller, PhD, Suresh S. Ramalingam, MD, Sai-Hong Ignatius Ou, MD, PhD, Kathryn F. Mileham, MD, Gregory J. Riely, MD, PhD

Get full text

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC by Dong-Wan Kim, MD, PhD, Shirish Gadgeel, MD, Scott N. Gettinger, MD, Gregory J. Riely, MD, PhD, Geoffrey R. Oxnard, MD, Tarek Mekhail, MD, Peter Schmid, MD, PhD, Afshin Dowlati, MD, Rebecca S. Heist, MD, MPH, Antoinette J. Wozniak, MD, Jatinder Singh, PhD, Edward Cha, MD, PhD, Jessica Spahn, PhD, Sai-Hong Ignatius Ou, MD, PhD

Get full text